Evidence map›Paper›PMID 41864056›Full record

Trial reportBreast (Edinburgh, Scotland)2026

Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).

Mark Opdam, Nigel Ultee, Jill J J Geenen, Annelot G J van Rossum, Ingrid A M Mandjes, Sara Balduzzi, Ingrid Hofland, Jelle Wesseling, Renee X Menezes, Hendrika M Oosterkamp and 2 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mark OpdamDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Nigel UlteeDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jill J J GeenenDivision of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Annelot G J van RossumDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ingrid A M MandjesData Center, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Sara BalduzziBiometrics Division, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ingrid HoflandCore Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jelle WesselingDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
Renee X MenezesBiostatistics Centre, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Hendrika M OosterkampDepartment of Medical Oncology, Haaglanden Medisch Centrum, The Hague, the Netherlands.
Sabine C LinnDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, University Medical Center, Utrecht, the Netherlands. Electronic address: s.linn@nki.nl.
MATADOR trialists' group for the Dutch Breast Cancer Research Group (BOOG)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntensified anthracycline-based regimens are as effective as standard anthracycline-based chemotherapy with taxanes in unselected high-risk patients with early breast cancer and come with their own toxicity profiles. Many biomarkers linked to taxane resistance have been identified, but none are used clinically. A predictive biomarker for taxane resistance or sensitivity would help personalise treatment.

methodsIn the randomised controlled trial MATADOR (ISRCTN61893718), 664 patients with pT1-3, pN0-3 breast cancer were treated with either docetaxel, doxorubicin, and cyclophosphamide (TAC) or dose-dense schedule of doxorubicin and cyclophosphamide (ddAC). IHC protocols for 13 previously proposed biomarkers (ABCB1, AR, BCL2, CyclinD1, EZH2, GSTP1, pH2AX, Ki67, MAPT, P53, Thioredoxin, TUBB, and TUBB3) were tested in all 577 clinical high-risk patients. The prognostic and predictive value was assessed in the total group, and in the hormone receptor-positive HER2-negative and in the triple-negative (TN) subgroup.

resultsPatients with TN EZH2

conclusionsPatients with TN EZH2 CLINICAL TRIAL IDENTIFICATION: MATADOR, ISRCTN61893718, BOOG 2005-02, CKTO 2004-04.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsAdultAgedChemotherapy, AdjuvantCyclophosphamideDisease-Free SurvivalDocetaxelDoxorubicinDrug Resistance, NeoplasmEnhancer of Zeste Homolog 2 ProteinErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunohistochemistryBiomarkers, TumorCyclophosphamideDocetaxelDoxorubicinEnhancer of Zeste Homolog 2 ProteinErb-b2 Receptor Tyrosine KinasesEZH2 protein, humanTaxoidsTUBB3 protein, humanTubulinEarly breast cancersEZH2Prognostic and predictive biomarkersTaxanesTubulins

Identifiers

PMID41864056
PMCPMC13185652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.